Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genome Diagnostics Laboratory, |
RCV001848441 | SCV002104710 | likely pathogenic | Hereditary spastic paraplegia | 2016-12-12 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003226496 | SCV003923156 | uncertain significance | not specified | 2024-03-14 | criteria provided, single submitter | clinical testing | Variant summary: GBA2 c.1A>T (p.Met1Leu) alters the initiation codon and is predicted to result either in absence of the protein or truncation of the encoded protein due to translation initiation at a downstream codon. The next potential in-frame start codon is located at Met9. To our knowledge, no pathogenic variants have been reported upstream of this codon. Three of three in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 5.9e-05 in 204400 control chromosomes. To our knowledge, no occurrence of c.1A>T in individuals affected with Spastic Paraplegia 46, Autosomal Recessive and no experimental evidence demonstrating its impact on protein function have been reported. ClinVar contains an entry for this variant (Variation ID: 1344338). Based on the evidence outlined above, the variant was classified as uncertain significance. |
Mayo Clinic Laboratories, |
RCV004793530 | SCV005410708 | uncertain significance | not provided | 2024-05-09 | criteria provided, single submitter | clinical testing | PM2, PVS1_supporting |